On May 5, 2025, UBS upgraded GE HealthCare Technologies (NasdaqGS:GEHC) from a **Sell** to a **Neutral** rating. The average one-year price target for the company is currently set at **$99.45** per share, indicating a potential **43.35%** upside from its latest closing price of **$69.37** per share.
Projected annual revenue for GE HealthCare is **$21,986 million**, reflecting an **11.05%** increase. Institutions reported ownership of **509,765K** shares, up **4.33%** over the last three months, with a total of **2,158** funds reporting positions in the company.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
